Green Thumb Industries (GTBIF) Cash & Equivalents (2018 - 2026)
Green Thumb Industries (GTBIF) posted Cash & Equivalents of $344.5 million for Q1 2026, up 25.6% on a QoQ basis from $274.3 million in Q4 2025, and up 63.6% year-over-year from $210.6 million in Q1 2025.
Green Thumb Industries (GTBIF) Cash & Equivalents (2018 - 2026) Analysis & Trends
Green Thumb Industries' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $344.5 million for Q1 2026.
- Quarterly Cash & Equivalents rose 63.6% year-over-year to $344.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $344.5 million (up 63.6% YoY) and the FY2025 annual result came in at $274.3 million, up 59.77% from the prior year.
- Cash & Equivalents was $344.5 million for Q1 2026 at Green Thumb Industries, up from $274.3 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $344.5 million in Q1 2026 and bottomed at $136.8 million in Q3 2023.
- A 5-year average of $192.7 million and a median of $176.9 million in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 59.55% — and 2026, when it surged 63.6%.
- Green Thumb Industries' Cash & Equivalents stood at $177.7 million in 2022, then dropped by 9.03% to $161.6 million in 2023, then climbed by 6.22% to $171.7 million in 2024, then soared by 59.77% to $274.3 million in 2025, then grew by 25.6% to $344.5 million in 2026.
- Business Quant data shows GTBIF's Cash & Equivalents at $344.5 million in Q1 2026, $274.3 million in Q4 2025, and $226.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Green Thumb Industries | 1.63 Bn | 1.29 Bn | 143.65 Mn | 344.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 344.51 Mn |
| Dec 31, 2025 | 274.30 Mn |
| Sep 30, 2025 | 226.21 Mn |
| Jun 30, 2025 | 176.92 Mn |
| Mar 31, 2025 | 210.58 Mn |
| Dec 31, 2024 | 171.69 Mn |
| Sep 30, 2024 | 173.64 Mn |
| Jun 30, 2024 | 196.14 Mn |
| Mar 31, 2024 | 223.94 Mn |
| Dec 31, 2023 | 161.63 Mn |
| Sep 30, 2023 | 136.84 Mn |
| Jun 30, 2023 | 149.03 Mn |
| Mar 31, 2023 | 185.37 Mn |
| Dec 31, 2022 | 177.68 Mn |
| Sep 30, 2022 | 147.26 Mn |
| Jun 30, 2022 | 145.28 Mn |
| Mar 31, 2022 | 174.54 Mn |
| Dec 31, 2021 | 230.42 Mn |
| Sep 30, 2021 | 285.79 Mn |
| Jun 30, 2021 | 359.19 Mn |